EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses

Kyle Flannery, Paul F Cavanaugh, Kevin Steele

Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1855-1856

DOI: 10.2967/jnumed.126.272999 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.09.2026. Verfasst von Kyle Flannery und 2 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TO THE EDITOR: We read with interest the recent publication by Gogebakan et al. ([1][1]) evaluating the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel from a U.S. health care perspective. We commend the authors for addressing a relevant health economic question. We agree with their

Zitieren

APA

Flannery, K., Cavanaugh, P. F., & Steele, K. (2026). Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses. Journal of Nuclear Medicine, 67(11), 1855-1856. https://doi.org/10.2967/jnumed.126.272999

Vancouver

Flannery K, Cavanaugh PF, Steele K. Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses. Journal of Nuclear Medicine. 2026;67(11):1855-1856. doi:10.2967/jnumed.126.272999

BibTeX
@article{Flannery2026,
  author = {Flannery, Kyle and Cavanaugh, Paul F and Steele, Kevin},
  title = {Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {11},
  pages = {1855--1856},
  doi = {10.2967/jnumed.126.272999}
}
Kostenlos starten →